OOIR: Observatory of International Research

Papers

(The H4-Index of Breast Cancer Research and Treatment is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Changes in expression of breast cancer tumor biomarkers between primary tumors and corresponding metastatic sites: common patterns and relationships with survival	80
Nuclear magnetic resonance-determined lipoprotein profile and risk of breast cancer: a Mendelian randomization study	78
Intraoperative assessment of axillary sentinel lymph nodes by telepathology	77
Prognostic and predictive impact of NOTCH1 in early breast cancer	66
Surveillance mammography after treatment for male breast cancer	63
Differential response of luminal and basal breast cancer cells to acute and chronic hypoxia	62
Comparative efficacy and safety of extended adjuvant endocrine therapy for hormone receptor-positive early breast cancer: a Bayesian network meta-analysis	59
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer	52
Inter-reader agreement of breast magnetic resonance imaging and contrast-enhanced mammography in breast cancer diagnosis: a multi-reader retrospective study	51
Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients	49
Long-term dietary intervention influence on physical activity in the Women’s Health Initiative Dietary Modification randomized trial	43
Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer	40
Uncovering novel pathogenic variants and pathway mutations in triple-negative breast cancer among the endogamous mizo tribe	40
Correction: Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy	40
Predicting the likelihood of carrying BRCA1 or BRCA2 pathogenic variants in high-risk Pakistani breast cancer patients	39
The association between cirrhosis and outcomes among female patients undergoing surgery for breast cancer in Ontario: a population-based study	37
Integrating SENOMAC and AMAROS: a call for de-escalation	37
Oncotype DX recurrence score in node-positive patients in the post-RxPONDER era: a single-institution experience	34
Endocrine adherence in male versus female breast cancer: a seer-medicare review	34
Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer	32
Methionine restriction exposes a targetable redox vulnerability of triple-negative breast cancer cells by inducing thioredoxin reductase	29
Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study	29
Area deprivation index and breast cancer outcomes among patients in Western New York	29
Premenopausal women with breast cancer in the early post-partum period show molecular profiles of invasion and are associated with poor prognosis	29
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy	29

Impact of environmental temperature on the survival outcomes of breast cancer: A SEER-based study	29
Temporal patterns of breast cancer incidence, mortality, disability-adjusted life years and risk factors in 12 South American Countries, 1990–2019: an examination using estimates from the global burde	28
Impact of pembrolizumab on ovarian function in young triple-negative breast cancer patients treated with chemo-immunotherapy	27
Therapeutic impact of 18F-FDG PET/CT for initial staging in patients with clinical stage I and IIA, HER2-positive, or triple-negative breast cancer	27